Viewing nowCombinationHugliam Tablets 50/500 mg (Sitagliptin, Metformin)
Sitagliptin Hydrochloride Hydrate 56.69mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Huons Co., Ltd.

MFDS item code 202300848 · Approved 2023.03.13 · Insurance code 670609100
Improvement of glycemic control in patients with type 2 diabetes mellitus
This drug is used as an adjunct to dietary restrictions and exercise therapy to improve blood sugar control in patients with type 2 diabetes. The combined action of sitagliptin and metformin helps manage blood sugar effectively. Continuous use can help stabilize blood sugar levels.
The dose of this medicine for antidiabetic therapy should be determined according to each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with meals. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. The initial dose of this medicine should be determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior experience with antidiabetic drug therapy who do not achieve adequate glycemic control with monotherapy, or for whom sitagliptin monotherapy does not provide adequate glycemic control, the initial dose of this medicine is 1 tablet of 50/500 mg twice daily. The dose may be increased to 1 tablet of 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see section 2. Patients who should not take this medicine under Precautions for Use). 2. Patients receiving metformin: - For patients who do not achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg) together with the patient's current metformin dose. - Patients switching from concomitant sitagliptin and metformin therapy to this medicine may start at their current doses of sitagliptin and metformin. 3. Patients who do not achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg), and the initial dose of metformin should take the patient's blood glucose level and current dose into consideration. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When this medicine is used in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see section 5. General Precautions under Precautions for Use). No studies have been conducted to evaluate the safety and efficacy of switching to this medicine in patients previously treated with other oral antihyperglycemic agents. Any change in the treatment regimen for type 2 diabetes may alter glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Because the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see section 2. Patients who should not take this medicine under Precautions for Use).
This drug consists of sitagliptin and metformin, and is used for diabetes treatment. First, the sitagliptin component may rarely cause serious allergic reactions, so if symptoms such as skin rash, difficulty breathing, or swelling of the face or lips occur within three months of administration, the use should be stopped immediately, and medical consultation should be sought. Additionally, sitagliptin can induce a condition called pancreatitis, which is inflammation of the pancreas, so if symptoms like abdominal pain, vomiting, or nausea occur, visit the hospital immediately. The metformin component can cause lactic acidosis, a rare but potentially fatal metabolic abnormality, so patients with poor kidney function, liver diseases, severe infections, or dehydration should not take this drug. Patients with moderate to severe renal impairment, acute heart failure, myocardial infarction, women who are pregnant or breastfeeding, and patients scheduled for tests using specific contrast agents should not use this medication. This drug carries a risk of hypoglycemia; therefore, caution is required when the amount of food intake is irregular or insufficient, during intense exercise, or when used in conjunction with other hypoglycemic agents. Moreover, this drug contains certain artificial dyes, so patients with a history of allergy to these components should use it cautiously. During treatment, regular kidney function and blood tests should be performed to monitor for abnormalities, and periodic checks of vitamin B12 levels are also advisable. Alcohol consumption may increase the risk of side effects from this drug, so it is important not to overindulge while taking it. If oral intake becomes difficult due to surgery, severe infection, or severe trauma, the medication should be temporarily discontinued, and can be resumed after recovery. If you experience sudden muscle pain, skin rash, severe headache, or dizziness while taking this drug, consult a physician immediately. Finally, this drug is not recommended for use in pediatric patients under 18 years of age, as safety and effectiveness have not been established.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in an airtight container, preferably at room temperature between 1 and 30 degrees Celsius. Proper storage helps maintain the integrity and effectiveness of the drug.
Bright pink oval film-coated tablet
Bottle - 100 tablets/bottle, Bottle - 30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSitagliptin Hydrochloride Hydrate 56.69mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Huons Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Korea Hutech Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.